Confo Therapeutics and AbCellera have entered a research partnership to discover GPCR [specific G protein-coupled receptor ligand]-targeting antibody candidates.
The collaboration will use Confo Therapeutics’ suite of ConfoBody-enabled antibody discovery technologies on two undisclosed GPCR targets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe ConfoBody technology will help to stabilise the selected GPCRs in their disease-relevant conformations.
These GPCRs will be leveraged as antigens for the discovery and development of antibodies.
Confo Therapeutics will be eligible to receive upfront payments, milestones and tiered royalties on the net sales of the product.
Confo Therapeutics CEO Cedric Ververken stated: “We are thrilled to start this collaboration with AbCellera to discover the best possible antibody candidates against two challenging GPCR targets.
“This serves as an additional validation, recognising the power of Confo’s platform and our ability to overcome the limitations of GPCR antibody discovery.
“Entering into select, high-value collaborations allows us to efficiently deploy our platform together with leading companies while we continue to build out our own pipeline of innovative and impactful medicines.”
Combined with pharmacologic and biologic insight, Confo Therapeutics’ platform allows the company to develop a multi-indication drug candidates pipeline with the aim of transforming therapeutic outcomes for patients living with severe illnesses.
In March 2023, Confo Therapeutics and Eli Lilly and Company entered a global licence agreement for the former’s clinical-stage peripheral pain candidate, CFTX-1554.
Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
